Holen Sie sich die Stockscreener-App
1.55
2.52%
-0.04
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CTXR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.59
Offen:
$1.59
24-Stunden-Volumen:
60,648
Relative Volume:
0.42
Marktkapitalisierung:
$13.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-39.14M
KGV:
-0.2596
EPS:
-5.97
Netto-Cashflow:
$-28.20M
1W Leistung:
-12.92%
1M Leistung:
-42.59%
6M Leistung:
-88.07%
1J Leistung:
-91.39%
1-Tages-Spanne:
$1.515
$1.70
1-Wochen-Bereich:
$1.515
$1.87
52-Wochen-Spanne:
$1.47
$26.75
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Firmenname
Citius Pharmaceuticals Inc
Sektor
Branche
Telefon
(908) 967-6676
Adresse
11 COMMERCE DRIVE, CRANFORD, NJ
Vergleichen Sie CTXR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
1.55 | 13.32M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2021-11-30 | Eingeleitet | Maxim Group | Buy |
Citius Pharmaceuticals Inc Aktie (CTXR) Neueste Nachrichten
Fisher Asset Management LLC Acquires Shares of 12,800 Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Citius Pharma Advances LYMPHIR Launch Amid Financial Updates - TipRanks
Biotech Alert: Searches spiking for these stocks today - TipRanks
Citius Pharmaceuticals (NASDAQ:CTXR) Given Buy Rating at D. Boral Capital - Defense World
Citius Pharma's LYMPHIR gains permanent J-code for billing - MSN
Citius Pharmaceuticals stock hits 52-week low at $2.43 By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals stock hits 52-week low at $2.43 - Investing.com India
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Oncology Inc. (CTOR) reports earnings - Quartz
Citius Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Citius Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update - Financial Times
Citius Pharmaceuticals (CTXR) Projected to Post Quarterly Earnings on Wednesday - Defense World
Citius Pharmaceuticals (NASDAQ:CTXR) Announces Issuance of Permanent J-Code for LYMPHIR by CMSOn February 6, 2025, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) disclosed in an 8-K filing that the company and its oncology subsidiary, Citius Oncol - Defense World
Citius Pharma’s LYMPHIR gains permanent J-code for billing By Investing.com - Investing.com Nigeria
Dr Reddy's Signed Agreement With Citius Pharma To Sell Anti-Cancer Drug - BW Healthcare World
Citius Pharma's LYMPHIR gains permanent J-code for billing By Investing.com - Investing.com Australia
Medicare Breakthrough: Citius's Cancer Drug LYMPHIR Gets Crucial Insurance CodeMajor Win for CTCL Patients - StockTitan
Amendment: SEC Form 10-K/A filed by Citius Pharmaceuticals Inc. - Quantisnow
Short Interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Expands By 13.6% - Defense World
Citius Pharmaceuticals (STU:47N0) Earnings Yield (Joel Gree - GuruFocus.com
Citius Pharmaceuticals Completes Registered Direct Offering, Raises $2.7 MillionOn January 7, 2025, Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced the closure of a securities purchase agreement with certain institutional investors for a regist - Defense World
Citius Pharmaceuticals’ (CTXR) Buy Rating Reiterated at D. Boral Capital - Defense World
Citius Pharma secures $3 million in direct offering By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals (NASDAQ: CTXR) Announces Progress in LYMPHIR Commercial Launch Preparation - Defense World
Why Citius Pharmaceuticals (CTXR) Stock Is Down 15% - Benzinga
Citius Pharma secures $3 million in direct offering - Investing.com
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - PR Newswire
Citius Pharmaceuticals Secures $3M Through Strategic Share Offering with 5-Year Warrants - StockTitan
Citius Pharma gears up for LYMPHIR immunotherapy launch By Investing.com - Investing.com Australia
Citius Pharma gears up for LYMPHIR immunotherapy launch - Investing.com
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 - PR Newswire
Citius Oncology to explore strategic alternatives - Yahoo Finance
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives - The Malaysian Reserve
Citius Oncology Explores Strategic Options with Jefferies Following LYMPHIR FDA Approval - StockTitan
Citius Pharma Reports 2024 Financial Results and Business Update - MSN
Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital - Yahoo Finance
Citius Pharmaceuticals (NASDAQ:CTXR) Upgraded to “Buy” at D. Boral Capital - Defense World
D. Boral Capital Upgrades Citius Pharmaceuticals (CTXR) - MSN
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday - Benzinga
American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls - Yahoo Finance
Citius Pharmaceuticals upgraded by D. Boral Capital with a new price target - Quantisnow
CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday - Benzinga
Citius Pharmaceuticals (NASDAQ: CTXR) Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - Defense World
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Oncology, Inc. Reports Earnings Results for the Full Year Ended September 30, 2024 - Marketscreener.com
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Re - GuruFocus.com
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Finanzdaten der Citius Pharmaceuticals Inc-Aktie (CTXR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.39%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):